MMS

MMS MMS is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach.

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for three consecutive years.

KerusCloud®, our clinical trial simulation platform that de-risks study design, has been named a finalist in the Fierce ...
10/16/2025

KerusCloud®, our clinical trial simulation platform that de-risks study design, has been named a finalist in the Fierce Life Sciences Innovation Awards under the Data Analytics and Business Intelligence category! 🏆

KerusCloud® empowers clinical teams to model and analyze thousands of virtual trial scenarios —optimizing endpoints, recruitment strategies, and estimand frameworks before a real study begins. The result? You get data-driven insights that accelerate development, reduce costs, and increase the likelihood of trial success in many ways.

As our CTO Mohamad Zahreddine put it: “We approach innovation by building practical, forward-looking tools that solve real challenges in clinical development, and we are grateful to the judges at the Fierce Innovation Awards for recognizing that!”

Congrats to the hard work of every member of the family who helped make this a reality!

Read more: https://hubs.li/Q03NXyJr0

View the full shortlist: https://hubs.li/Q03NXx6v0

OCT New England 2025 kicks off today in Boston!MMS is proud to sponsor this year’s event, joining biotech and pharma lea...
10/15/2025

OCT New England 2025 kicks off today in Boston!

MMS is proud to sponsor this year’s event, joining biotech and pharma leaders to explore the future of clinical outsourcing.

Visit us at Booth #76 to meet our onsite team: Ben Dudley, Duane Robinson, and Kyle Arenofsky

Don’t miss tomorrow’s featured session: Chris Schoonmaker, MMS COO, presents at 11:30 AM ET in the Clinical Technology & Innovation Stream:
“3 Technology Use Cases Shaping the Future of Trial Design and Implementation”

🔗 https://hubs.li/Q03NGcFT0

Let’s connect and talk smarter trial design, in-stream decision-making, and AI-driven innovation.

Next week, MMS colleagues will be attending the 13th Annual Outsourcing in Clinical Trials Nordics 2025 from Arena Inter...
10/14/2025

Next week, MMS colleagues will be attending the 13th Annual Outsourcing in Clinical Trials Nordics 2025 from Arena International!

More than 200 people will be on hand in Denmark to discuss strategies for operational success in the pharma, biotech, and medical device communities. From our team, Harry Brown will be part of the conversation to discuss regulatory and data strategies in Europe and beyond.

Learn more about the event here: https://hubs.li/Q03NryhC0
Message us here to schedule a meeting: https://hubs.li/Q03Nrvcd0

Are you looking to join a company where your contributions truly matter, and where you'll be part of a supportive, innov...
10/13/2025

Are you looking to join a company where your contributions truly matter, and where you'll be part of a supportive, innovative team? MMS is an award-winning, data-focused clinical research organization (CRO). We pride ourselves on being a Great Place to Work certified organization, recognized for our exceptional culture and industry leading employee retention rate.

We’re looking for a Nonclinical Writer to support the development, writing, and management of highly technical nonclinical documents. This is a full-time, remote position for candidates based out of either the UK or the US.

Learn more about this and other open roles at https://hubs.li/Q03Nd95m0

Accelerated regulatory pathways require strategic choices. Are you ready to navigate them? Join MMS in an upcoming webin...
10/10/2025

Accelerated regulatory pathways require strategic choices. Are you ready to navigate them? Join MMS in an upcoming webinar hosted by Citeline on October 21 to explore how sponsors can make smarter decisions across Fast Track, Breakthrough Therapy Designation, Accelerated Approval, Priority Review, EMA’s PRIME, and more.

This session is packed with insights from MMS experts on how to:

➡️ Select the right regulatory path at the right time
➡️ Align protocols and endpoints to meet expectations
➡️ Use early signals to support stronger submissions

Thank you to Sam Miller, Ben Kaspar, and Ben Dudley for lending their insights on how data, modeling, and regulatory strategy intersect to drive progress!

Save your seat now: https://hubs.li/Q03N4kPv0

Early development is where investor confidence is often won or lost, and our recent Perspectives article, “Design to De-...
10/09/2025

Early development is where investor confidence is often won or lost, and our recent Perspectives article, “Design to De-Risk, The Fastest Way to Earn Investor Trust,” highlights how simulation and scenario planning give sponsors a clear narrative for investor conversations.

Take a look and understand:

✅ Endpoints that reflect the true benefit to patients
✅ Assumptions tested under multiple conditions
✅ Visible alignment between CMOs and statisticians

Explore the full article now at https://hubs.li/Q03MHJxQ0

ICYMI: Last month, MMS announced that it has joined forces with Friends of Cancer Research to build decision frameworks ...
10/08/2025

ICYMI: Last month, MMS announced that it has joined forces with Friends of Cancer Research to build decision frameworks that support earlier, clearer interpretation of interim overall survival data in oncology trials.

Our teams used simulation modeling to stress-test scenarios like crossover and delayed benefit so clinical trial leaders and regulators can make more informed choices earlier. These tools aim to reduce ambiguity in trial design, strengthen regulatory discussions, and help patients gain access to therapies with confidence.

Read the full announcement here: https://hubs.li/Q03MHCsX0

There are just 10 days to go until the 17th Annual Outsourcing in Clinical Trials New England 2025 in Boston! MMS is pro...
10/07/2025

There are just 10 days to go until the 17th Annual Outsourcing in Clinical Trials New England 2025 in Boston! MMS is proud to be a featured sponsor of this year’s event, where our own Chris Schoonmaker will present: “3 Technology Use Cases Shaping the Future of Trial Design and Implementation.”

Chris will share how data-driven modeling, real-time operational insights, and AI are driving smarter, more efficient, and more adaptive trials.

Details here: https://hubs.li/Q03Mv95S0

What does a career in data science look like inside a global CRO? We’re glad you asked!In a recent Perspectives article,...
10/07/2025

What does a career in data science look like inside a global CRO? We’re glad you asked!

In a recent Perspectives article, Shervin Maleki walks us through his path from biomedical engineering to leading-edge data science at MMS. He shares what drives his work, the challenges and opportunities of supporting sponsors, and how AI is transforming the field.

Discover his story here: https://hubs.li/Q03Mv9Zg0

We’re excited to share that MMS will be attending the 20th Clinical Trials Strategic Summit (CTSS), taking place on 8–9 ...
10/06/2025

We’re excited to share that MMS will be attending the 20th Clinical Trials Strategic Summit (CTSS), taking place on 8–9 October 2025 at The Westin San Francisco Airport, California.

MMS will be represented by Aiden Flynn, Ben Kaspar, and Nimish Sidpura, who will be engaging with peers and stakeholders to discuss how we’re advancing clinical trial excellence through our biometrics and regulatory services.

We’re looking forward to meaningful conversations with industry peers and exploring opportunities to collaborate on the future of clinical research.

Interested in connecting with our team on site? Reach out via our contact page: https://hubs.li/Q03Mg4kn0

We’re proud to announce our role in supporting Gates Ventures, the Alzheimer's Disease Data Initiative, and the Global N...
10/02/2025

We’re proud to announce our role in supporting Gates Ventures, the Alzheimer's Disease Data Initiative, and the Global Neurodegeneration Proteomics Consortium (GNPC) to deliver one of the world’s largest proteomic datasets for neurodegenerative diseases!

MMS supported the data intake, harmonization, and anonymization of over 250 million protein measurements from 35,000 biosamples across more than 20 international cohorts, including Alzheimer’s, Parkinson’s, ALS, and Frontotemporal Dementia.

“Neurodegenerative diseases affect tens of millions globally, yet progress in treatment has been slowed by fragmented data and limited biomarker discovery. The GNPC Harmonized Dataset marks a major step forward in addressing these challenges by uniting proteomic data at scale,” said Dr. Farhad Imam, Director of Health and Life Sciences at Gates Ventures. “This was a technically ambitious effort, and MMS’ expertise and ability to execute on high volume and high complexity data harmonization made them instrumental in delivering this dataset and supporting positive patient impact globally.”

Read the full announcement: https://hubs.li/Q03LV4BG0

Clinical trials in pulmonary disease often face uncertainty, especially when data is limited! Simulation-ready models av...
10/02/2025

Clinical trials in pulmonary disease often face uncertainty, especially when data is limited! Simulation-ready models available through KerusCloud give research teams the ability to run design scenarios using real-world distributions.

Teams can explore design options, assess variability, and determine sample size with greater clarity. That leads to faster decisions, more efficient timelines, and a stronger case when engaging with regulators!

Take a look for yourself to see how KerusCloud supports simulation-driven trial planning: https://hubs.li/Q03LsbYX0

Address

6880 Commerce Boulevard
Canton, MI
48187

Telephone

+17342450310

Website

Alerts

Be the first to know and let us send you an email when MMS posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to MMS:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

MMS is an award-winning, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating and was named as the Best Global Biotech CRO in the 2018 International Life Sciences Awards.